BIIB - Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript
2024-02-13 12:25:05 ET
Biogen Inc. (BIIB)
Q4 2023 Earnings Conference Call
February 13, 2024 8:00 AM ET
Company Participants
Chuck Triano - Head of Investor Relations
Chris Viehbacher - President and Chief Executive Officer
Priya Singhal - Head of Development
Mike McDonnell - Chief Financial Officer
Conference Call Participants
Marc Goodman - Leerink Partners
Salveen Richter - Goldman Sachs
Umer Raffat - Evercore ISI
Evan Seigerman - BMO Capital Markets
Phil Nadeau - TD Cowen
Michael Yee - Jefferies
Colin Bristow - UBS
Chris Raymond - Piper Sandler
Mohit Bansal - Wells Fargo
Presentation
Operator
Good morning. My name is Katie and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Full-Year 2023 Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Today's conference is being recorded.
Thank you. I would now like to turn the conference over to Mr. Chuck Triano, Head of Investor Relations. Mr. Triano, you may begin your conference.
Chuck Triano
Thank you, Katie. Good morning and welcome to Biogen's fourth quarter and full-year 2023 earnings call. Before we begin, I'll remind you that the earnings release and related financial tables including our GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today are located in the Investors section of biogen.com.
Our GAAP financials are provided in tables 1 and 2, and table 4 includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We have also posted the slides on our website that will be used during this call.
I would like to point out also that we will be making forward-looking statements, which are based on our expectations. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
On today's call, I'm joined by our President and Chief Executive Officer, Chris Viehbacher; Dr. Priya Singhal, Head of Development; and our CFO, Mike McDonnell. Chris, Priya, and Mike will each make some opening comments and then we'll move to the Q&A session. To allow us to get through as many questions as possible, we ask that you limit yourself to one question.
With that, I’ll now turn the call over to Chris.
Chris Viehbacher
Thank you, Chuck. Good morning, everybody. A year ago, I had the -- an opportunity of presenting Biogen's quarterly results for the first time. At that time, we expressed the objective of returning Biogen to sustainable growth. And I think in the intervening year we've made substantial progress and today it is a great amount of pride and pleasure that we can announce earnings guidance, which Mike will go into in greater detail, which says that we will -- we are expecting to see positive earnings per share growth....
Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript